Evaluation of Endometriosis With 18F-fluorofuranylnorprogesterone PET / MRI
NCT05480995
· ctgov
active_not_recruiting
phase phase-2
- Enrollment
- 9
- Start
- 2023-01-17
- Completion
- 2026-08-01
- Last updated
- 2026-08-28
- Has results
- False
- Countries
- United States
Conditions
Tagged with
Interventions
-
18F-fluorofuranylnorprogesterone PET / MRI
DRUG
Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
Eligibility criteria
Inclusion Criteria
* Age 18 or older
* Female of childbearing age (18-55 years)
* Clinically suspected (symptomatic) endometriosis as defined by referring physician (this would also include endometriomas as other disease may be present).
* Scheduled for planned operative laparoscopy with no hormone treatment for at least two cycles
* Able to provide informed consent
Exclusion Criteria
* Male
* Institutionalized subject (prisoner or nursing home patient)
* Known history of breast, ovarian or endometrial cancer.
* Pregnant or breast-feeding women
* Chronic progestin-containing medications or Gonadotropin-releasing hormone (GnRH) analogues in the last 10-16 days (or 2 cycles in the case of GnRH analogues as these are dosed monthly) or inability to discontinue these medications
* Allergy to gadolinium contrast or Glomerular Filtration Rate (GFR) below 30 ml/min.
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine
Courtesy of ClinicalTrials.gov / U.S. National Library of Medicine